Toni K. Choueiri
托尼·舒艾里
MD
Director, Lank Center for Genitourinary Oncology; Jerome and Nancy Kohlberg Professor of Medicine, Harvard Medical School; Senior Physician, Dana-Farber Cancer Institute兰克泌尿生殖肿瘤中心主任，哈佛医学院Jerome and Nancy Kohlberg医学教授，丹娜-法伯癌症研究院资深医师
👥Biography 个人简介
Toni K. Choueiri, MD is Director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute and Jerome and Nancy Kohlberg Professor of Medicine at Harvard Medical School. He is one of the most prolific and influential kidney cancer researchers in the world, having led or co-led dozens of pivotal clinical trials spanning multiple therapeutic classes. He was the principal investigator for JAVELIN Renal 101, the phase III trial demonstrating that avelumab combined with axitinib improved progression-free survival over sunitinib in first-line metastatic RCC. He was also a key investigator in the pivotal trials of belzutifan (PT2977/MK-6482), the first-in-class oral HIF-2α inhibitor that received FDA approval for VHL disease-associated RCC—an entirely new mechanism of action targeting the upstream oncogenic driver of clear cell RCC. Dr. Choueiri co-developed and validated the IMDC (International Metastatic RCC Database Consortium) prognostic model that replaced the MSKCC criteria as the global standard. He also led landmark studies characterizing clear cell RCC molecular subtypes, identifying immune-inflamed versus angiogenic/stromal versus mTOR gene expression profiles with differential therapeutic implications. He has published over 600 peer-reviewed papers.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
JAVELIN Renal 101 — Avelumab+Axitinib as First-Line Standard in Metastatic RCC
Served as principal investigator for JAVELIN Renal 101, demonstrating that avelumab plus axitinib significantly improved progression-free survival over sunitinib in first-line metastatic RCC across PD-L1-positive and overall populations, leading to FDA and EMA approval and establishing a third IO+VEGFR first-line option.
HIF-2α Inhibition with Belzutifan — A New Mechanistic Class in VHL-Mutated RCC
Played a pivotal role in the clinical development of belzutifan (MK-6482), the first oral HIF-2α inhibitor, demonstrating clinically meaningful objective response rates in VHL disease-associated RCC, pNETs, and hemangioblastomas; contributing to FDA approval and establishing HIF-2α as an actionable target distinct from VEGFR and mTOR pathways.
IMDC Prognostic Model Co-Development and Global Validation
Co-developed the International Metastatic RCC Database Consortium (IMDC) prognostic model—incorporating six clinical and laboratory variables—that stratifies patients into favorable, intermediate, and poor-risk categories. The IMDC model became the universal stratification tool in contemporary RCC clinical trials, replacing the MSKCC criteria in the targeted therapy era.
Molecular Subtypes of Clear Cell RCC and Transcriptome-Based Immunotherapy Prediction
Led comprehensive molecular characterization of clear cell RCC identifying three transcriptomic subtypes—ccRCC1 (angiogenic), ccRCC2 (stromal/EMT), and ccRCC3 (immune-inflamed)—with distinct prognoses and differential sensitivity to VEGFR inhibitors versus immunotherapy, providing a framework for biomarker-driven treatment selection.
Representative Works 代表性著作
Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma (JAVELIN Renal 101)
New England Journal of Medicine (2019)
Phase III JAVELIN Renal 101 trial establishing avelumab plus axitinib as a first-line standard for advanced RCC, demonstrating superior PFS across PD-L1-positive and overall populations versus sunitinib.
Belzutifan for renal cell carcinoma in von Hippel-Lindau disease
New England Journal of Medicine (2021)
Pivotal trial of belzutifan (HIF-2α inhibitor) in VHL disease-associated RCC demonstrating clinically meaningful objective responses and tolerability, leading to FDA approval of a novel mechanism of action.
Validation of the IMDC (International Metastatic Renal Cell Carcinoma Database Consortium) model in patients receiving first-line sunitinib
European Urology (2013)
Validation study of the IMDC prognostic model in the sunitinib era, establishing it as the standard risk stratification tool replacing MSKCC criteria in contemporary RCC trials.
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in renal cell carcinoma
Nature Medicine (2019)
Comprehensive molecular analysis of the IMmotion150 trial identifying angiogenic, immune, and stromal gene expression signatures predictive of response to atezolizumab+bevacizumab versus sunitinib in advanced RCC.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-04-06 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 托尼·舒艾里 的研究动态
Follow Toni K. Choueiri's research updates
留下邮箱，当我们发布与 Toni K. Choueiri（Dana-Farber Cancer Institute / Harvard Medical School）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment